期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟达拉滨联合MP方案治疗复发难治性多发性骨髓瘤疗效分析 被引量：1

原文传递
导出
摘要 目的 氟达拉滨联合MP方案治疗复发难治的多发性骨髓瘤患者的疗效观察.方法 17例复发难治的多发性骨髓瘤患者接受氟达拉滨联合MP方案（每一疗程氟达拉滨35 mg/d×5 d或50 mg/d×3 d,静脉滴注,马法兰2 mg/d×7 d,口服,强的松25 mg/次,2次/d×7 d,口服）治疗.结果 17例患者中2例失访.另15例中2例在一疗程FMP方案治疗后取得了疗效进步.1例治疗后效果仍不理想.其余12例病情未再进展.17例患者中2例因严重肺部感染,呼吸衰竭死亡.结论 氟达拉滨联合MP方案一定程度上可改善复发难治的多发性骨髓瘤患者的病况,为患者争取进一步治疗提供机会.
作者 苏基滢 张曦 周立宇 徐黎 宋陆茜 常春康
机构地区 上海交通大学附属上海市第六人民医院血液科
出处 《中国医师杂志》 CAS 2011年第12期1698-1699,共2页 Journal of Chinese Physician
关键词 阿糖腺苷/类似物和衍生物/投药和剂量 美法仑/投药和剂量 泼尼松/投药和剂量 多发性骨髓瘤/药物疗法
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1周亚丽,彭志刚.核苷类似物治疗多发性骨髓瘤的研究进展[J].医学综述,2007,13(3):209-211. 被引量：1
  • 2Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia, 2006, 20 (9) : 1467 -1473.
  • 3Maisey N, Cunningham D. Current therapy and future prospects in lymphoma. Expert Rev Anticancer Ther,2001,1 ( 1 ) :29-41.
  • 4Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine , mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATI') regimen in patients with stage IV indolent lymphoma. Blood,2002,100 ( 13 ) :4351-4357.
  • 5罗绍凯,李娟,洪文德,赵莹,童秀珍.FND方案治疗难治性、复发性多发性骨髓瘤的初步报告[J].癌症,2005,24(12):1518-1521. 被引量：14
  • 6Bjorkstrand B, Rasmussen T, Remes K, et al. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma:a randomized phase pilot study. Eur J Haematol,2003,70 (6) :379-383.
  • 7Krett NL,Ayres M, Nabhan C, et al. In vitro assessment of nucleo side analogs in multiple myeloma. Cancer Chemother Pharmacel, 2004,54(2) :113-121.
  • 8Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibitionof nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res, 1996, 2 (10) : 1731- 1741.
  • 9Tallman MS, Hakimian D. Purine nualeoside analogs: emerging roles in indolent lympho proliferative disorders. Blood, 1995,86 ( 7 ) : 2463-2474.
  • 10Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia, 2001, 15(6): 875-890.

二级参考文献22

  • 1王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学（输血及血液学分册）,1993,16(1):35-37. 被引量：11
  • 2罗绍凯,李娟,洪文德,赵莹,童秀珍.FND方案治疗难治性、复发性多发性骨髓瘤的初步报告[J].癌症,2005,24(12):1518-1521. 被引量：14
  • 3Klasa R J, Meyer RM, Shustik C, et al. Randomized phase Ⅲ study of fludarabine phosphate versus cyclophosphamide,vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen [J]. J Clin Oncol, 2002,20 (24): 4649-4654.
  • 4Bjorkstrand B, Rasmussen T, Remes K, et al. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomized phase Ⅱ study [J]. Eur J Haematol,2003,70(6): 379-383.
  • 5Durie BG, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mess with presenting clinical features response to treatment and survival[J]. Cancer, 1975,36(3):842-854.
  • 6Giles FJ. Refractory multiple myeloma:recent advances in therapy [J]. Hematol Pathol, 1995,9(3-4): 121-140.
  • 7Alas S,Bonavida B.Inhibition of constitutive STAT3 activity sensitizes resistant Non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis[J].Clin Cancer Res,2003,9(1):316-326.
  • 8Hillmen P.Future prospects for fludarabine-containing regimens in the treatment of hematological cancers[J].Hematol J,2004,5 (Suppl 1):S76-S86.
  • 9Tsimberidou AM,McLaughlin P,Younes A,et al.Fludarabine,mitoxantrone,dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage Ⅳ indolent lymphoma[J].Blood,2002,100(13):4351-4357.
  • 10Bjorkstrand B,Rasmussen T,Remes K,et al.Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma:a randomized phase pilot study[J].Eur J Haematol,2003,70(6):379-383.

共引文献13

同被引文献8

引证文献1

二级引证文献1

中国医师杂志
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部